Cytek Biosciences (CTKB) Operating Expenses (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Operating Expenses data on file, last reported at $39.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 13.05% year-over-year to $39.7 million; the trailing twelve-month figure through Mar 2026 stood at $149.4 million (up 12.34% YoY), and the FY2025 full-year result was $144.8 million, up 10.04% from the prior year.
• Operating Expenses for Q1 2026 stood at $39.7 million, up from $38.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $39.7 million in Q1 2026 and bottomed at $22.5 million in Q1 2022.
• The 5-year median for Operating Expenses is $33.6 million (2023), against an average of $32.7 million.
• The widest annual swing landed in 2022, when Operating Expenses surged 68.74%; it then declined 8.92% in 2024.
• A 5-year view of Operating Expenses shows it stood at $29.3 million in 2022, then advanced by 13.3% to $33.2 million in 2023, then dropped by 7.59% to $30.7 million in 2024, then climbed by 25.48% to $38.5 million in 2025, then advanced by 3.22% to $39.7 million in 2026.
• The last three Operating Expenses figures came in at $39.7 million (Q1 2026), $38.5 million (Q4 2025), and $36.7 million (Q3 2025), per Business Quant data.

Peer Comparison